Table 3.
Adverse effects of CAR-T and their management
| Patient | Cytopenia (AE grading) |
CRS (AE grading) |
CRES | CRS grading | Use of IL-6R inhibitor |
Use of glucocorticoid |
| 1 | PLT↓ (3) | Fever (3), Diarrhea (2), Creatinine ↑ (1), Abnormal coagulation (1) | No | 2 | Yes | Yes |
| 2 | WBC↓ (3) | Fever (2), Hypoxia (3), Chill (1), Heart failure (3), hypotension (3) | No | 3 | No | Yes |
| 3 | No | No | No | 0 | No | No |
| 4 | WBC↓ (2), NEU↓ (3), PLT↓ (3), LYM ↓ (2) |
Fever (2), Hypoglobulinemia (1) | No | 1 | No | No |
| 5 | No | Fever (1), Bilirubin ↑ (1), D-Dimer (1), LDH ↑ (1),α-HBDH ↑ (1) | No | 1 | No | No |
| 6 | No | No | No | 0 | No | No |
| 7 | WBC↓ (4), NEU↓ (4), PLT↓ (4), LYM↓ (3), MON↓ (2) |
Fever (2) | No | 1 | No | No |
| 8 | WBC↓ (4), NEU↓ (4), PLT↓ (4), LYM ↓ (4) |
Fever (1), NT-BNP (1) | No | 2 | No | No |
| 9 | LYM ↓ (4) | Fever (2) | No | 1 | No | No |
↓ indicates decrease; ↑ indicates increase.
The grading of AE was according to the CTCAE V.4.03.
AEs, adverse events; CRES, CAR-related encephalopathy syndrome; CRS, cytokine release syndrome; α-HBDH, α hydroxybutyrate dehydrogenase; LDH, lactate dehydrogenase; LYM, lymphocyte; NEU, neutrophil count; NT-BNP, N-terminal B-type natriuretic peptide; PLT, platelet count; WBC, white blood cell.